B cell superantigens subvert innate functions of B cells

Chemical Immunology and Allergy

Volumn 93, Issue 1, 2007, Pages 92-105

  Zouali, Moncef ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BACTERIAL PROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; PROTEIN L; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS PROTEIN A; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; IG L BINDING PROTEIN, PEPTOSTREPTOCOCCUS; IG L-BINDING PROTEIN, PEPTOSTREPTOCOCCUS; IMMUNOGLOBULIN HEAVY CHAIN;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACTERIAL GENE; BACTERIAL VIRULENCE; BINDING SITE; CELL PROLIFERATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS MAGNUS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE ACTIVATION; ANIMAL; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; REVIEW; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; BACTERIAL PROTEINS; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; STAPHYLOCOCCAL PROTEIN A; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 34249745162     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000100860     Document Type: Article

References (60)

1. HIII subgroup. J Immunol 1991;147:1877-1883.
2. Nilson BH, Solomon A, Bjorck L, Akerstrom B: Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J Biol Chem 1992;267:2234-2239.
3. H3 gene products: Natural ligands for HIV gp120. Science 1993;261:1588-1591.
4. Zouali M: B-cellIsuperantigens: implications for selection of the human antibody repertoire. Immunol Today 1995;16:399-405.
5. Marrack P, Kappler J: The staphylococcal enterotoxins and their relatives. Science 1990;248: 705-711.
6. Karray S, Zouali M: Identification of the B cell superantigen-binding site of HIV-1 gp120. Proc Natl Acad Sci USA 1997;94:1356-1360.
7. Juompan L, Lambin P, Zouali M: Selective alterations of the antibody response to HIV-1. Appl Biochem Biotechnol 1998;75:139-150.
8. Juompan L, Lambin P, Zouali M: Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB J 1998;12:1473-1480.
9. Bessudo A, Rassenti L, Havlir D, Richman D, Feigal E, Kipps TJ: Aberrant and unstable expression of immunoglobulin genes in persons infected with human immunodeficiency virus. Blood 1998;92:1317-1323.
10. Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, Zouali M: Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol 1998;161:6681-6688.
11. H3 gene repertoire of naive human B cells. J Immunol 2000;164:5482-5491.
12. Viau M, Zouali M: Molecular determinants of the human antibody response to HIV-1: Implications for disease control. J Clin Immunol 2001;21:410-419.
13. Crossley KB, Archer GL: The Staphylococci in Human Diseases. New York, Churchill Livingstone, 1997.
14. Archer GL: StaphylocoAcus aureus: a well-armed pathogen. Clin Infect Dis 1998;26:1179-1181.
15. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998;339:520-532.
16. Vidal MA, Conde FP: Alternative mechanism of protein A-immunoglobulin interaction: The VH-associated reactivity of a monoclonal human IgM. J Immunol 1985;135:1232-1238.
17. Green LL, Jakobovits A: Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes. J Exp Med 1998;188:483-495.
18. Gallo ML, Ivanov VE, Jakobovits A, Davis CG: The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans. Eur J Immunol 2000;30: 534-540.
19. Viau M, Longo NS, Lipsky PE, Zouali M: Staphylococcal protein a deletes B-1a and marginal zone B lymphocytes expressing human immunoglobulins: an immune evasion mechanism. J Immunol 2005;175:7719-7727.
20. Zouali M: Natural antibodies; in Nature Publishing Group: Encyclopedia of Life Sciences. London, Nature Publishing Group, Macmillan Reference Ltd, pp 638-643. http://www.els.net.
21. McDaniel LS, Benjamin WH Jr, Forman C, Briles DE: Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol 1984;133:3308-3312.
22. Paciorkowski N, Porte P, Shultz LD, Rajan TV: B1 B lymphocytes play a critical role in host protection against lymphatic filarial parasites. J Exp Med 2000;191:731-736.
23. Benedict CL, Kearney JF: Increased junctional diversity in fetal B cells results in a loss of protective anti-phosphorylcholine antibodies in adult mice. Immunity 1999;10:607-617.
24. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen J: A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998;188:2381-2386.
25. Viau M, Zouali M: B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 2005;114: 17-26.
26. Amano M, Baumgarth N, Dick MD, Brossay L, Kronenberg M, Herzenberg LA, Strober S: CD1 expression defines subsets of follicular and marginal zone B cells in the spleen: Beta 2-microglobulin-dependent and independent forms. J Immunol 1998;161:1710-1717.
27. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, Lamers MC, Carsetti R: B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999;190:75-89.
28. Oliver AM, Martin F, Kearney JF: IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol 1999;162:7198-7207.
29. Won WJ, Kearney JF: CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice. J Immunol 2002;168:5605-5611.
30. MacLennan IC, Liu YJ: Marginal zone B cells respond both to polysaccharide antigens and protein antigens. Res Immunol 1991;142:346-351.
31. Kraal G: Cells in the marginal zone of the spleen. Int Rev Cytol 1992;132:31-74.
32. Gray D, McConnell I, Kumararatne DS, MacLennan IC, Humphrey JH, Bazin H: Marginal zone B cells express CR1 and CR2 receptors. Eur J Immunol 1984;14:47-52.
33. Waldschmidt TJ, Kroese FG, Tygrett LT, Conrad DH, Lynch RG: The expression of B cell surface receptors. 3. The murine low-affinity IgE Fc receptor is not expressed on Ly 1 or 'Ly 1-like' B cells. Int Immunol 1991;3:305-315.
34. Snapper CM, Yamada H, Smoot D, Sneed R, Lees A, Mond JJ: Comparative in vitro analysis of proliferation, Ig secretion, and Ig class switching by murine marginal zone and follicular B cells. J Immunol 1993;150:2737-2745.
35. Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF: Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 1997;27: 2366-2374.
36. Guinamard R, Okigaki M, Schlessinger J, Ravetch JV: Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 2000;1:31-36.
37. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T: Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001;412:826-831.
38. Girkontaite I, Missy K, Sakk V, Harenberg A, Tedford K, Potzel T, Pfeffer K, Fischer KD: Lsc is required for marginal zone B cells, regulation of lymphocyte motility and immune responses. Nat Immunol 2001;2:855-862.
39. Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, Honjo T: Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol 2002;3:443-450.
40. Kuroda K, Han H, Tani S, Tanigaki K, Tun T, Furukawa T, Taniguchi Y, Kurooka H, Hamada Y, Toyokuni S, Honjo T: Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003;18:301-312.
41. Viau M, Longo NS, Lipsky PE, Bjorck L, Zouali M: Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect Immun 2004;72:3515-3523.
42. Bjorck L: Protein L. A novel bacterial cell wall protein with affinity for Ig L chains. J Immunol 1988;140:1194-1197.
43. Graille M, Stura EA, Housden NG, Beckingham JA, Bottomley SP, Beale D, Taussig MJ, Sutton BJ, Gore MG, Charbonnier JB: Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure 2001;9:679-687.
44. Patella V, Casolaro V, Bjorck L, Marone G: Protein L. A bacterial Ig-binding protein that activates human basophils and mast cells. J Immunol 1990;145:3054-3061.
45. Genovese A, Bouvet JP, Florio G, Lamparter-Schummert B, Bjorck L, Marone G: Bacterial immunoglobulin superantigen proteins A and L activate human heart mast cells by interacting with immunoglobulin E. Infect Immun 2000;68:5517-5524.
46. Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, Ayling C, Goyenechea B, Xian J, Taussig MJ, Neuberger MS, Bruggemann M: Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 1999;163:6898-6906.
47. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-574.
48. Weber AK, Wahn U, Renz H: Superantigen-induced T cell death by apoptosis: Analysis on a single cell level and effect of IFN-gamma and IL-4 treatment. Int Arch Allergy Immunol 2000;121: 215-223.
49. Lin YT, Wang CT, Hsu CT, Wang LF, Shau WY, Yang YH, Chiang BL: Differential susceptibility to staphylococcal superantigen (SsAg)-induced apoptosis of CD4+ T cells from atopic dermatitis patients and healthy subjects: The inhibitory effect of IL-4 on SsAg-induced apoptosis. J Immunol 2003;171:1102-1108.
50. Varadhachary AS, Perdow SN, Hu C, Ramanarayan M, Salgame P: Differential ability of cell subsets to undergo activation-induced cell death. Proc Natl Acad Sci USA 1997;94:5778-5783.
51. Zhang X, Brunner T, Carter L, Dutton RW, Rogers P, Bradley L, Sato T, Reed JC, Green D, Swain SL: Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997;185:1837-1849.
52. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-482.
53. Tanguay DA, Colarusso TP, Pavlovic S, Irigoyen M, Howard RG, Bartek J, Chiles TC, Rothstein TL: Early induction of cyclin D2 expression in phorbol ester-responsive B-1 lymphocytes. J Exp Med 1999;189:1685-1690.
54. Martin F, Kearney JF: B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a 'natural immune memory'. Immunol Rev 2000;175:70-79.
55. Mond JJ, Lees A, Snapper CM: T cell-independent antigens type 2. Annu Rev Immunol 1995;13: 655-692.
56. Rajewsky K: Clonal selection and learning in the antibody system. Nature 1996;381:751-758.
57. Cariappa A, Tang M, Parng C, Nebelitskiy E, Carroll M, Georgopoulos K, Pillai S: The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity 2001;14:603-615.
58. Martin F, Kearney JF: Selection in the mature B cell repertoire. Curr Top Microbiol Immunol 2000;252:97-105.
59. Viau M, Zouali M: Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol Immunol 2005;42:849-855.
60. Viau M, Veas F, Zouali M: Impact of inactivated HIV-1 virions on B cells. Mol Imunol 2007;44:2134-2144.